Skip To Main Content
Jarushka Naidoo on Muck Rack

Jarushka Naidoo

As seen in: Nature, Wiley Online Library, MDPI, The BMJ, JAMA Oncology, Medscape, Future Medicine, CURE Magazine, OncLive, EMJ- European Medical Journal and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jarushka

Contact Jarushka, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

AI-based augmentation of oncology clinical trials

|
By Andrea Villa, Ashley L. Eadie, David Synnott, Rebecca Romano, Max Piffoux, Naomi Scheinerman, Daniel Tan, Miriam Koopman, Jarushka Naidoo, Madhusmita Behera, Selen Bozkurt, Susan Halabi, Rodrigo Dienstmann, Loic Verlingue, Arsela Prelaj, Ravi Parikh Verified
| Nature Verified
Abstract Oncology clinical trials are often characterized by slow accrual, high failure rates and limited generalizability, reflecting both biological complexity and operational inefficiencies. Advances in artificial intelligence (AI) — enabled by large-scale electronic health record datasets and machine learning methods — offer new opportunities to address these challenges across the clinical trial lifecycle.
Open in Who Shared Issue with article?

Cytokine release syndrome in solid tumors

|
By David Synnott, David O’Reilly, Declan de Freitas, Jarushka Naidoo
| Wiley Online Library Verified
INTRODUCTION Over the past decade, cancer immunotherapy has marked a major advance in cancer treatment. This has resulted in incremental improvements in outcomes for patients, particularly in melanoma, lung cancer, renal cell cancer and others.1-3 Therapies like immune checkpoint inhibitors (ICIs), bispecific T-cell engaging antibodies (BiTEs), and adoptive cell therapies (ACT), including chimeric antigen receptor (CAR) T-cells, exemplify this progress.
Open in Who Shared Issue with article?

50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic

|
By Jarushka Naidoo, Dipesh Uprety, Matthew P. Smeltzer, Abesh Niroula
| jto.org
Keywords Non–small cell lung cancer Progress 50 Years Thoracic Oncology Introduction The past 50 years have seen a dramatic evolution in thoracic oncology (Fig. 1). We have gone from a time of limited understanding of the biology of lung cancer, no demonstrated benefits for screening, and marginal benefits from therapy to an era of molecular profiling, survival benefits from low-dose computed tomography (CT) screening, and a steadily expanding list of therapeutic options.
Open in Who Shared Issue with article?
See all 26 licensed articles (41 Total)